Anavex Life Sciences Corporation AVXL Fundamentals and Key Ratios

Anavex Life Sciences Corp. (AVXL) Fundamentals


Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2.

SHARE INFORMATION
Market Cap	$ 824,634,983
Shares Outstanding	77,942,815
Float	75,782,139
Percent Float	97.23%
Short Interest	0.00
Short Percent Float	0.0%
Short Interest Ratio	0.00
Short Interest Date	-
Latest Fiscal Dividend Per Share	$ 0.00
Latest Fiscal Revenue	$ 0
Latest Fiscal EPS	$ -0.53
Latest Fiscal Date	2021-09-30

DIVIDENDS
Dividend (3 Years)	$ 0.00
Dividend (5 Years)	$ 0.00
Ex Dividend Date	-
Dividend Rate	$ 0.00
Dividend Yield	0.0%
Payment Cash	-

HOLDERS
Institutions	300
Institutional Holdings Date	2022-07-31
Institutional Bought Previous 3 Months	4,508,522
Institutional Holdings Percent	56.8%
Institutional Sold Previous 3 Months	3,419,355
Insider Holdings Date	2022-07-31
Insider Bought Previous 3 Months	250,000
Insider Holdings Percent	13.1
Insider Sold Previous 3 Months	-
Insider Shares Owned	10,162,410

TRADING INFO
52 Week High	$ 23.73
52 Week Low	$ 7.13
52 Week High Change	$ -43.75
21 Day Moving Average	$ 11.0143
21 Day Extended Moving Average	$ 11.0957
50 Day Moving Average	$ 10.599
50 Day Extended Moving Average	$ 10.7817
200 Day Moving Average	$ 12.8009
200 Day Extended Moving Average	$ 11.9849
10 Day Average Volume	769,730
20 Day Average Volume	742,518
30 Day Average Volume	812,752
50 Day Average Volume	913,819
Alpha	0.029295
Beta	0.7906
Standard Deviation	0.233348
R2	0.028713
7 Day Price Change	$ -0.41
7 Day Percent Change	-3.73%
21 Day Price Change	$ -0.05
21 Day Percent Change	-0.47%
30 Day Price Change	$ -0.02
30 Day Percent Change	-0.19%
Month to Date Price Change	$ 0.32
Month to Date Percent Change	3.12%
Quarter to Date Price Change	$ 0.57
Quarter to Date Percent Change	5.69%
180 Day Price Change	$ -0.81
180 Day Percent Change	-7.11%
200 Day Price Change	$ -1.59
200 Day Percent Change	-13.06%
Year to Date Price Change	$ -6.76
Year to Date Percent Change	-38.99%

Anavex Life Sciences Corp. (AVXL) Key Ratios

PROFITABILITY
EBIT Margin	0.0%
EBITDA Margin	0.0%
Pre-Tax Profit Margin	0.0%
Profit Margin Count	0.0%
Gross Margin	0.0%
Profit Margin TOT	0.0%

INCOME STATEMENTS
Revenue	$ 0
Revenue Per Share	$ 0.00
Revenue (3 Years)	$ 0.00
Revenue (5 Years)	$ 0.00

FINANCIAL STRENGTH
Price to Tangible Book	5.70
Total Debt To Equity	0.00
Int Coverage	0.00
Current Ratio	16.90
Leverage Ratio	1.10
Quick Ratio	16.80
Long Term Debt To Capital	0.00

VALUATION MEASURES
PE Ratio	-18.70
Enterprise Value	$ 708,848,181
Price to Sales	0.00
Price to Free Cash	-30.90
PE High Last 5 Years	-10.50
Price To Book	5.70
Price To Cash Flow	0.00
PE Low Last 5 Years	-8.80
Price to Tangible Book	5.70

MANAGEMENT EFFECTIVENESS
Receivables Turnover	0.00
Invoice Turnover	0.00
Assets Turnover	0.00
Return Assets	-29.55
Return on Equity	-31.36
Return on Capital	-29.59

Anavex Life Sciences Corp. (AVXL) Profile

PROFILE INFO
Issue Type	CS
SEC Type	EQS
Auditor	BDO USA, LLP
CEO	Christopher U. Missling
Emplyoees	25
Last Audit	UQ
CIK	0001314052
Industry	Biotechnology
Sector	Healthcare
NAICS	Pharmaceutical Preparation Manufacturing(325412)

CONTACT INFO
Address	51 West 52nd Street 7th Floor New York, NY 10019
Website	https://www.anavex.com
Facsimile	-
Telephone	+1 844 689-3939
Email	ir@anavex.com